1 enrolling by invitation. 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 1 | Enrolling by invitation 1 |
Follow Myotonia: new trials by email Literature Review of Myotonia trials Research Report on Myotonia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of Long-term Safety and Efficacy of VX-670 in Participants With Myotonic Dystrophy Type I VX-670 - Myotonic Dystrophy Type 1 (DM1) | Phase 2 | Enrolling by invitation | Vertex Pharmaceuticals Incorporated | 44 | 2025-04-28 | 2026-10-14 |
Genetic Diseases, Inborn (1) · Heredodegenerative Disorders, Nervous System (1) · Muscular Diseases (1) · Muscular Disorders, Atrophic (1) · Muscular Dystrophies (1) · Musculoskeletal Diseases (1) · Myotonic Disorders (1) · Myotonic Dystrophy (1) · Nervous System Diseases (1) · Neurodegenerative Diseases (1) · Neuromuscular Diseases (1)
Congenital, Hereditary, and Neonatal Diseases and Abnormalities (1) · Neurologic Manifestations (1) · Neuromuscular Manifestations (1) · Pathological Conditions, Signs and Symptoms (1) · Signs and Symptoms (1)
Vertex Pharmaceuticals Incorporated (1)
Australia (1) · Belgium (1) · Canada (1) · Germany (1) · Netherlands (1) · Spain (1) · United Kingdom (1) · United States (1)